RenovaCare, Inc. operates as a development stage company, which engages in the research, development, and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The company is headquartered in Scottsdale, Arizona and currently employs 1 full-time employees. The company went IPO on 2000-08-08. The firm is focused on developing autologous (self-donated) stem cell therapies for the regeneration of human organs. The firm through its wholly owned subsidiary, RenovaCare Sciences Corp. is focusing on the research, development and commercialization of autologous (using a patient’s own cells) cellular therapies that can be used for medical and aesthetic applications. The Company’s CellMist System is a cell isolation procedure that enzymatically renders stem cells from the patient’s own skin or other tissues. The resulting stem cell suspension is administered topically from the Company’s novel solution sprayer device (the SkinGun) as a cell therapy for wounds including burns to facilitate healing. Its SkinGun spray device is an advanced technology, using a gentle positive-pressure air stream to spray the CellMist Solution onto wounds.